TMEFF2 was identified and characterized by at least five independent groups within the time span of approximately a year.

An inverse correlation between TMEFF2 methylation and the stage, response to therapy and survival outcome has been observed.

[5] The detection of methylated free-circulating TMEFF2 DNA has been suggested as a potential diagnostic tool for colorectal cancer.

The TMEFF2 downregulation signature equals and sometimes outperforms the Gleason and pathological scores in prostate cancer.

Through binding the amyloid β protein, its precursor and derivatives, TMEFF2 provides neuroprotection in Alzheimer's disease.